Generic entry - a challenge to traditional EU competition law | Practical Law

Generic entry - a challenge to traditional EU competition law | Practical Law

Traditionally, the market entry of a generic pharmaceutical brings about a 30% to 40% shift in market share from the innovative pharmaceutical company to the generic firm, along with a 20% (in the first year after generic entry) to 25% (in the second year after generic entry) reduction in the average medicine price. With patent term expiries fully underway, innovative market players increasingly have recourse to a toolbox of strategies.

Generic entry - a challenge to traditional EU competition law

Practical Law UK Articles 8-500-7752 (Approx. 20 pages)

Generic entry - a challenge to traditional EU competition law

by Anne Lamote, Peter L'Ecluse and Catherine Longeval, Van Bael & Bellis
Law stated as at 01 Nov 2010 • European Union, United Kingdom, USA (National/Federal)
Traditionally, the market entry of a generic pharmaceutical brings about a 30% to 40% shift in market share from the innovative pharmaceutical company to the generic firm, along with a 20% (in the first year after generic entry) to 25% (in the second year after generic entry) reduction in the average medicine price. With patent term expiries fully underway, innovative market players increasingly have recourse to a toolbox of strategies.
This article is part of the PLC multi-jurisdictional guide to Life Sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifescienceshandbook.